VENOUS THROMBOEMBOLISM
TREATMENT
About the Disease
Venous Thromboembolism (VTE) is a blood clot that starts in a vein. It is an underdiagnosed and serious yet preventable medical condition. While VTE is rare in children, VTE in pediatrics is becoming a recognized cause of significant morbidity and mortality in children. Most children diagnosed with VTE have a serious underlying illness such as cancer, chronic total parenteral nutrition dependency, or congenital heart disease.
About our Patient Care
Our dedicated VTE Care Team will work with the physician's office and insurance on a patient's behalf so that our patients and their caregivers have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance. As part of the treatment, we provide the following:
Dedicated Care Team
We provide prescribers and patients with a dedicated VTE Care Team, including a primary pharmacy contact, clinical education, side-effects management, scheduled refill calls, and a direct phone, fax, and email address.
Shipping and Coordination of Care
We provide free overnight delivery of medications and necessary medical supplies and manage the coordination of care between prescribers, sites of care, nurses and patients to ensure dispenses and drug delivery align with the date and location of service.
Financial Assistance
We successfully identify and assist enrolling patients into any and all manufacturer co-pay and foundation support programs in order to minimize a potential financial burden to patients given the high-cost of specialty medications.
24/7/365 Access to an Orsini Pharmacist
We provide prescribers and patients access to a pharmacist 24/7/365 to ensure patients are always cared for.
Supported Treatments
Click on the specialty drug name below to expand and see more information.
Pradaxa® (dabigatran etexilate) oral pellets
Brand Name | Pradaxa® (dabigatran etexilate) oral pellets
Manufacturer | Boehringer Ingelheim
Route of Administration | oral pellets
Approved Indication |
1. For the treatment of venous thromboembolic events (VTE) in pediatric patients aged three months to less than 12 years of age who have been treated with a parenteral anticoagulant for at least five days.
2. To reduce the risk of recurrence of VTE in pediatric patients aged three months to less than 12 years of age who have been previously treated.
Self-Administration | Yes
Product Website | www.boehringer-ingelheim.com